Navigation Links
Nastech to Host 2007 Analyst and Institutional Investor Day
Date:9/26/2007

BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. - 3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West 43rd Street. The luncheon event will feature a presentation from Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer and Gordon Brandt, M.D., Executive Vice President, Clinical Research and Medical Affairs of Nastech as well as the following leading scientific experts:

-- Robert S. Lindsay, M.B.Ch.B., Ph.D., F.R.C.P., Chief of Internal

Medicine, Helen Hayes Hospital and Director of its Clinical Research

Center, and Professor of Clinical Medicine, Columbia University, will

provide an overview of osteoporosis and give expert insight on the use

of Parathyroid Hormone (PTH1-34) as a therapy for this disease.

-- Zachary T. Bloomgarden, M.D., Clinical Professor,

Medicine/Endocrinology Diabetes and Bone Disease, Department of

Medicine, Mount Sinai Medical Center, will present on diabetes and

discuss current treatment regimens for the disease as well as those

being developed.

-- Carl D. Novina, M.D., Ph.D., Assistant Professor, Cancer Immunology and

AIDS, Dana-Farber Cancer Institute, and Assistant Professor, Department

of Pathology, Harvard Medical School, will present on the emerging

field of RNA interference (RNAi) and its potential application as a

therapeutic.

"Nastech continues to make significant progress in its peptide and protein therapeutic programs utilizing our non-injectable drug delivery technology as well as the development of RNAi therapeutics and now has a strong pipeline of products in or preparing to initiate Phase II clinical trials," stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. "For this year's analyst and institutional investor day event, Nastech is pleased to have gathered leading experts in their respective fields to highlight three areas at the core of Nastech's drug development. This event will also lend insight into Nastech's technologies and business, as we continue to execute upon a strategy that we believe has the potential to deliver important therapies to patients while creating significant value for our shareholders."

The invitation-only event will be webcast commencing at 12:30 p.m. Eastern Time. To access the live webcast for this conference, please log on to Nastech's website at http://www.nastech.com approximately 15 minutes prior to the presentation in order to register and download any necessary software.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners, LLC

Matthew Haines (Investors/Media)

(212) 845-4235


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. measurement of green fluorescent proteins and a red fluorescent protein in live cells in the Analyst GT multimode reader
2. Venture Investors early-stage fund grows to $115 million
3. Investor warns of angel-venture funding gap
4. Brazilian bio-industry should impress American investors
5. Investors raise $25 million for biodiesel plant
6. Bio-energy and cleantech grab attention of investors
7. Venture Investors to open Michigan office
8. Early-stage executives hear from investors
9. Commerce qualifies seven for investor tax credits
10. Investor links East Coast funds to Midwest tech
11. Angel investors commit $12.7B in first half of `06
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):